BVF Inc’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-3,629,000
Closed -$21.2M 81
2022
Q4
$21.2M Hold
3,629,000
0.89% 36
2022
Q3
$24.3M Hold
3,629,000
1% 33
2022
Q2
$15.3M Buy
3,629,000
+1,376,000
+61% +$5.44M 0.74% 38
2022
Q1
$7.59M Hold
2,253,000
0.3% 62
2021
Q4
$7.1M Buy
+2,253,000
New +$7.5M 0.26% 60
2019
Q3
Sell
-1,628,187
Closed -$19.5M 61
2019
Q2
$19.5M Buy
1,628,187
+242,700
+18% +$2.61M 2.13% 15
2019
Q1
$16.7M Buy
1,385,487
+235,042
+20% +$3.46M 1.87% 19
2018
Q4
$14.4M Sell
1,150,445
-441,693
-28% -$6.1M 1.89% 16
2018
Q3
$23.6M Sell
1,592,138
-225,000
-12% -$3.54M 2.08% 19
2018
Q2
$30.6M Sell
1,817,138
-114,985
-6% -$2.23M 2.98% 12
2018
Q1
$44.2M Sell
1,932,123
-37,666
-2% -$838K 4.49% 8
2017
Q4
$51M Sell
1,969,789
-1,165,500
-37% -$23.5M 6.14% 5
2017
Q3
$46.2M Buy
3,135,289
+1,278,394
+69% +$18.6M 5.88% 5
2017
Q2
$25.9M Sell
1,856,895
-479,714
-21% -$7.07M 4.02% 10
2017
Q1
$39.9M Sell
2,336,609
-279,640
-11% -$3.35M 6.78% 5
2016
Q4
$26.9M Sell
2,616,249
-106,961
-4% -$978K 5.41% 5
2016
Q3
$27.5M Sell
2,723,210
-32,108
-1% -$351K 5.19% 8
2016
Q2
$30.9M Hold
2,755,318
6.59% 5
2016
Q1
$37.6M Buy
2,755,318
+523,304
+23% +$7.53M 9.31% 2
2015
Q4
$42.3M Sell
2,232,014
-23,154
-1% -$503K 7.22% 4
2015
Q3
$42.3M Sell
2,255,168
-266,284
-11% -$4.53M 8.55% 5
2015
Q2
$37.5M Buy
2,521,452
+1,180,793
+88% +$18M 6.63% 5
2015
Q1
$20.3M Buy
1,340,659
+134,200
+11% +$1.87M 4.25% 9
2014
Q4
$16.1M Hold
1,206,459
3.13% 12
2014
Q3
$15.2M Buy
+1,206,459
New +$11.7M 3.16% 11

BVF Inc's CNCE Position: Q1 2023 in Review

BVF Inc sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 3,629,000 shares — an estimated $21.2M sold.

BVF Inc first reported a position in CNCE in Q3 2014 and held it in 25 quarters. The position peaked at $51M in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

  • BVF Inc reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • BVF Inc sold 3,629,000 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $21.2M.
  • BVF Inc first reported a position in Concert Pharmaceuticals, Inc. in Q3 2014 and held it in 25 quarters.
  • BVF Inc's Concert Pharmaceuticals, Inc. position peaked at $51M in Q4 2017.
  • 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on BVF Inc's 13F filing for Q1 2023, filed 15 May 2023.